Vanguard Global Advisers
TELO icon

Vanguard Global Advisers’s Telomir Pharmaceuticals TELO Stock Holding History

Vanguard Global Advisers’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.39K Hold
6,552
– – ﹤0.01% 3504
2026
Q1 		$8.52K Buy
+6,552
New +$8.36K ﹤0.01% 3499

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Vanguard Global Advisers's TELO Position: Q2 2026 in Review

Vanguard Global Advisers held its Telomir Pharmaceuticals (TELO) position steady in Q2 2026 at 6,552 shares worth $8.39K. The position accounts for ﹤0.01% of the portfolio, ranked #3504.

Vanguard Global Advisers first reported a position in TELO in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.52K in Q1 2026. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • Vanguard Global Advisers held 6,552 shares of Telomir Pharmaceuticals worth $8.39K as of Q2 2026.
  • Vanguard Global Advisers left its Telomir Pharmaceuticals share count unchanged in Q2 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3504 holding.
  • Vanguard Global Advisers first reported a position in Telomir Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Telomir Pharmaceuticals position peaked at $8.52K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.